162 related articles for article (PubMed ID: 7486907)
1. Partial characterization and effect of omeprazole on ATPase activity in Helicobacter pylori by using permeabilized cells.
Belli WA; Fryklund J
Antimicrob Agents Chemother; 1995 Aug; 39(8):1717-20. PubMed ID: 7486907
[TBL] [Abstract][Full Text] [Related]
2. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori.
Iwahi T; Satoh H; Nakao M; Iwasaki T; Yamazaki T; Kubo K; Tamura T; Imada A
Antimicrob Agents Chemother; 1991 Mar; 35(3):490-6. PubMed ID: 2039199
[TBL] [Abstract][Full Text] [Related]
3. Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells.
Nagata K; Satoh H; Iwahi T; Shimoyama T; Tamura T
Antimicrob Agents Chemother; 1993 Apr; 37(4):769-74. PubMed ID: 8494373
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationship of omeprazole and analogues as Helicobacter pylori urease inhibitors.
Kühler TC; Fryklund J; Bergman NA; Weilitz J; Lee A; Larsson H
J Med Chem; 1995 Dec; 38(25):4906-16. PubMed ID: 8523404
[TBL] [Abstract][Full Text] [Related]
5. Bismuth subcitrate and omeprazole inhibit Helicobacter pyloriF1-ATPase.
Beil W; Birkholz C; Wagner S; Sewing KF
Pharmacology; 1995 May; 50(5):333-7. PubMed ID: 7667394
[TBL] [Abstract][Full Text] [Related]
6. Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor.
Tsuchiya M; Imamura L; Park JB; Kobashi K
Biol Pharm Bull; 1995 Aug; 18(8):1053-6. PubMed ID: 8535394
[TBL] [Abstract][Full Text] [Related]
7. Helicobacter pylori augments the acid inhibitory effect of omeprazole on parietal cells and gastric H(+)/K(+)-ATPase.
Beil W; Sewing KF; Busche R; Wagner S
Gut; 2001 Feb; 48(2):157-62. PubMed ID: 11156634
[TBL] [Abstract][Full Text] [Related]
8. Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori.
Nakao M; Malfertheiner P
Helicobacter; 1998 Mar; 3(1):21-7. PubMed ID: 9546114
[TBL] [Abstract][Full Text] [Related]
9. The H+, K(+)-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole.
Simon WA; Büdingen C; Fahr S; Kinder B; Koske M
Biochem Pharmacol; 1991 Jul; 42(2):347-55. PubMed ID: 1650212
[TBL] [Abstract][Full Text] [Related]
10. Antibacterial properties of lansoprazole alone and in combination with antimicrobial agents against Helicobacter pylori.
Nakao M; Tada M; Tsuchimori K; Uekata M
Eur J Clin Microbiol Infect Dis; 1995 May; 14(5):391-9. PubMed ID: 7556227
[TBL] [Abstract][Full Text] [Related]
11. The chemotherapeutic effects of H+/K+ inhibitors on Helicobacter pylori infection.
Logan RP
Pharmacol Ther; 1996; 69(1):79-83. PubMed ID: 8857304
[TBL] [Abstract][Full Text] [Related]
12. Omeprazole may exert both a bacteriostatic and a bacteriocidal effect on the growth of Helicobacter pylori (NCTC 11637) in vitro by inhibiting bacterial urease activity.
Mirshahi F; Fowler G; Patel A; Shaw G
J Clin Pathol; 1998 Mar; 51(3):220-4. PubMed ID: 9659264
[TBL] [Abstract][Full Text] [Related]
13. Basis for the selective antibacterial activity in vitro of proton pump inhibitors against Helicobacter spp.
Sjøstrøm JE; Kühler T; Larsson H
Antimicrob Agents Chemother; 1997 Aug; 41(8):1797-801. PubMed ID: 9257764
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory action of lansoprazole and its analogs against Helicobacter pylori: inhibition of growth is not related to inhibition of urease.
Nagata K; Takagi E; Tsuda M; Nakazawa T; Satoh H; Nakao M; Okamura H; Tamura T
Antimicrob Agents Chemother; 1995 Feb; 39(2):567-70. PubMed ID: 7726537
[TBL] [Abstract][Full Text] [Related]
15. The proton pump inhibitor omeprazole inhibits acid survival of Helicobacter pylori by a urease-independent mechanism.
McGowan CC; Cover TL; Blaser MJ
Gastroenterology; 1994 Nov; 107(5):1573-8. PubMed ID: 7926527
[TBL] [Abstract][Full Text] [Related]
16. Bactericidal activity of lansoprazole and omeprazole against Helicobacter pylori in vitro.
Vogt K; Hahn H
Arzneimittelforschung; 1998 Jun; 48(6):694-7. PubMed ID: 9689430
[TBL] [Abstract][Full Text] [Related]
17. By 1023/SK&F 96022: biochemistry of a novel (H+ + K+)-ATPase inhibitor.
Simon WA; Keeling DJ; Laing SM; Fallowfield C; Taylor AG
Biochem Pharmacol; 1990 Jun; 39(11):1799-806. PubMed ID: 2160820
[TBL] [Abstract][Full Text] [Related]
18. In-vitro activity of lansoprazole against Helicobacter pylori.
Figura N; Crabtree JE; Dattilo M
J Antimicrob Chemother; 1997 May; 39(5):585-90. PubMed ID: 9184356
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of gastric K+/H+-ATPase by acid-activated 2-((2-pyridylmethyl)sulphinyl)benzimidazole products.
Beil W; Hannemann H; Mädge S; Sewing KF
Eur J Pharmacol; 1987 Jan; 133(1):37-45. PubMed ID: 3030771
[TBL] [Abstract][Full Text] [Related]
20. Conservation and diversity of the Helicobacter pylori copper-transporting ATPase gene (copA) sequence among Helicobacter species and Campylobacter species detected by PCR and RFLP.
Ge Z; Jiang Q; Taylor DE
Helicobacter; 1996 Jun; 1(2):112-7. PubMed ID: 9398888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
